Weight loss gummies claim to burn fat, suppress hunger, and boost your metabolism to help with weight loss, but these ...

Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan: Boston Friday, March 21, 2025, 16:00 Hrs [IST] Rhythm Pharmaceuticals, Inc ...

US biotech Rhythm Pharmaceuticals (Nasdaq: RYTM) has reacquired the rights to its obesity treatment Imcivree (setmelanotide) ...

- Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission - - Strengthened ...

Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

The analyst cited optimism around the Phase 3 trial results for setmelanotide in Hypothalamic Obesity to be one of the ...

Rhythm Pharmaceuticals received an orphan-drug designation from Japan's Ministry of Health, Labour and Welfare for its treatment for a certain type of obesity. The Boston-based biopharmaceutical ...

scPharmaceuticals reported a net loss of $18.8 million for the fourth quarter of 2024, compared to $13.8 million for the fourth quarter of 2023. For the full-year 2024, scPharmaceuticals reported a ...

BOSTON - Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company specializing in rare neuroendocrine diseases with a current market capitalization of $3.51 billion and impressive 68% ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company focused on developing precision therapies for rare genetic obesity disorders caused by melanocortin-4 ...